Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).

Fig. 3

Post Lu-177 PSMA RLT SPECT/CT images

Figures 3a and 3b show the axial views of the SPECT/CT images at 24 and 96 h post Lu-177 PSMA RLT administration. Figures 3c and 3d show the coronal views of the SPECT/CT images at 24 and 96 h post Lu-177 PSMA RLT administration. There was no uptake in the prostate on the SPECT/CT images taken 4 h after the Lu-177 PSMA RLT administration

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us